Compare JPMorgan Equity Premium Income ETF (JEPI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Smith & Nephew plc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 4.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and Smith & Nephew plc for 121 Days on average.
| JEPI | SNN | |
|---|---|---|
Market Cap | $45.55B | $11.10B |
Volume | 3,820,809 | 1,051,703 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $37.17 |
52-Week Low | $55.29 | $26.42 |
Typical Hold Time | 57 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.67, up 0.39% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend distributions with recent payments of $0.37 per share. Recent media coverage focuses on JEPI's role in income strategies and tax implications of dividend reinvestment.
The covered-call strategy provides income but may limit upside during rallies. Current sentiment is mixed with institutional interest growing but technical indicators suggesting caution. Key risks include interest rate sensitivity and the trade-off between income generation and capital appreciation potential.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
